Literature DB >> 32275931

ADAR1 Transcriptome editing promotes breast cancer progression through the regulation of cell cycle and DNA damage response.

Eduardo A Sagredo1, Alfredo I Sagredo1, Alejandro Blanco2, Pamela Rojas De Santiago2, Solange Rivas3, Rodrigo Assar2, Paola Pérez2, Katherine Marcelain4, Ricardo Armisén5.   

Abstract

RNA editing has emerged as a novel mechanism in cancer progression. The double stranded RNA-specific adenosine deaminase (ADAR) modifies the expression of an important proportion of genes involved in cell cycle control, DNA damage response (DDR) and transcriptional processing, suggesting an important role of ADAR in transcriptome regulation. Despite the phenotypic implications of ADAR deregulation in several cancer models, the role of ADAR on DDR and proliferation in breast cancer has not been fully addressed. Here, we show that ADAR expression correlates significantly with clinical outcomes and DDR, cell cycle and proliferation mRNAs of previously reported edited transcripts in breast cancer patients. ADAR's knock-down in a breast cancer cell line produces stability changes of mRNAs involved in DDR and DNA replication. Breast cancer cells with reduced levels of ADAR show a decreased viability and an increase in apoptosis, displaying a significant decrease of their DDR activation, compared to control cells. These results suggest that ADAR plays an important role in breast cancer progression through the regulation of mRNA stability and expression of those genes involved in proliferation and DDR impacting the viability of breast cancer cells.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Breast cancer; DNA damage response; Proliferation; RNA editing; RNA stability

Year:  2020        PMID: 32275931     DOI: 10.1016/j.bbamcr.2020.118716

Source DB:  PubMed          Journal:  Biochim Biophys Acta Mol Cell Res        ISSN: 0167-4889            Impact factor:   4.739


  7 in total

1.  Compartment-specific and ELAVL1-coordinated regulation of intronic polyadenylation isoforms by doxorubicin.

Authors:  Alina Chakraborty; Mandy Cadix; Sébastien Relier; Nicolò Taricco; Tina Alaeitabar; Alexandre Devaux; Céline M Labbé; Sylvain Martineau; Amélie Heneman-Masurel; Pierre Gestraud; Alberto Inga; Nicolas Servant; Stéphan Vagner; Martin Dutertre
Journal:  Genome Res       Date:  2022-07-20       Impact factor: 9.438

Review 2.  ADAR1 and its implications in cancer development and treatment.

Authors:  Allison R Baker; Frank J Slack
Journal:  Trends Genet       Date:  2022-04-19       Impact factor: 11.821

3.  Transcriptome Profiling of ADAR1 Targets in Triple-Negative Breast Cancer Cells Reveals Mechanisms for Regulating Growth and Invasion.

Authors:  Allison R Baker; Christos Miliotis; Julia Ramírez-Moya; Talia Marc; Ioannis S Vlachos; Pilar Santisteban; Frank J Slack
Journal:  Mol Cancer Res       Date:  2022-06-03       Impact factor: 6.333

4.  ADAR1 Prevents R-loop Accumulation-Driven ATR Pathway Activation in Ovarian Cancer.

Authors:  Hanwei Cui; Qian Yi; Min Tian; Hai Ting Yang; Yuteng Liang; Jie Huang; Qi Zeng; Weichao Sun; Jian Han; Jianxin Guo; Zhiying Yu; Wenlan Liu; Xiufeng Ye
Journal:  J Cancer       Date:  2022-04-24       Impact factor: 4.478

5.  Investigation of SRP9 protein expression in breast cancer.

Authors:  Gizem Erdoğan; Didem Can Trabulus; Canan Kelten Talu; Mehmet Güven
Journal:  Mol Biol Rep       Date:  2021-11-02       Impact factor: 2.316

6.  Elevated expression of minichromosome maintenance 3 indicates poor outcomes and promotes G1/S cell cycle progression, proliferation, migration and invasion in colorectal cancer.

Authors:  He Zhou; Yongfu Xiong; Guangjun Zhang; Zuoliang Liu; Lifa Li; Songlin Hou; Tong Zhou
Journal:  Biosci Rep       Date:  2020-07-31       Impact factor: 3.840

7.  Upregulation of ADAR Promotes Breast Cancer Progression and Serves as a Potential Therapeutic Target.

Authors:  Xiao Li; Guangshun Sun; Liangliang Wu; Guoqiang Sun; Ye Cheng; Jing Tao; Zhouxiao Li; Weiwei Tang; Hanjin Wang
Journal:  J Oncol       Date:  2021-09-27       Impact factor: 4.375

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.